SEC Form SC 13G/A filed by Exact Sciences Corporation (Amendment)

$EXAS
Medical Specialities
Health Care
Get the next $EXAS alert in real time by email
SC 13G/A 1 tv0891-exactsciencescorp.htm SCHEDULE 13G/A exactsciencescorp

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934
(Amendment No.: 11)*

Name of issuer:  Exact Sciences Corp

Title of Class of Securities:  Common Stock

CUSIP Number:  30063P105

Date of Event Which Requires Filing of this Statement: December 29, 2023

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on the following page(s))

 

 

13G

CUSIP No.:  30063P105

1.  NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

The Vanguard Group - 23-1945930

2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

A. 

B.  X

3.  SEC USE ONLY

4.  CITIZENSHIP OF PLACE OF ORGANIZATION

Pennsylvania

(For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

5.  SOLE VOTING POWER

0

6.  SHARED VOTING POWER

125,252

7.  SOLE DISPOSITIVE POWER

17,156,979

8.  SHARED DISPOSITIVE POWER

402,772

9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

17,559,751

10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

N/A

11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

9.71%

12.  TYPE OF REPORTING PERSON

IA

 

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G
Under the Securities Act of 1934

Item 1(a) - Name of Issuer:

Exact Sciences Corp

Item 1(b) - Address of Issuer's Principal Executive Offices:

5505 Endeavor Lane
Madison, WI 53719

Item 2(a) - Name of Person Filing:

The Vanguard Group - 23-1945930

Item 2(b) – Address of Principal Business Office or, if none, residence:

100 Vanguard Blvd.
Malvern, PA 19355

Item 2(c) – Citizenship:

Pennsylvania

Item 2(d) - Title of Class of Securities:

Common Stock

Item 2(e) - CUSIP Number

30063P105

Item 3 - Type of Filing:

This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

Item 4 - Ownership:

  (a) Amount Beneficially Owned:

  (b) Percent of Class:

 

 

(c)  Number of shares as to which such person has:

(i)  sole power to vote or direct to vote:  

(ii)  shared power to vote or direct to vote:  

(iii)  sole power to dispose of or to direct the disposition of:  

(iv)  shared power to dispose or to direct the disposition of:  

Comments:

The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

Item 5 - Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

No one other person's interest in the securities reported herein is more than 5%.

Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

Not applicable

Item 8 - Identification and Classification of Members of Group:

Not applicable

Item 9 - Notice of Dissolution of Group:

Not applicable

Item 10 - Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date:  February 13, 2024

By /s/ Ashley Grim
Name: Ashley Grim
Title:  Head of Global Fund Administration

Get the next $EXAS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EXAS

DatePrice TargetRatingAnalyst
3/13/2025$52.00Sector Perform
RBC Capital Mkts
1/23/2025$70.00Overweight
Barclays
8/28/2024$75.00Overweight
Wells Fargo
6/27/2024$70.00Sector Outperform
Scotiabank
6/3/2024$75.00Buy
Jefferies
1/2/2024$91.00Hold → Buy
The Benchmark Company
12/14/2023$90.00Buy
Guggenheim
12/13/2023$95.00Outperform
Wolfe Research
More analyst ratings

$EXAS
Press Releases

Fastest customizable press release news feed in the world

See more
  • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

    SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

    $EXAS
    $QTRX
    $SERA
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2025 Gallup Exceptional Workplace Award (GEWA), marking the second year in a row the company has received this prestigious recognition. This award recognizes the most engaged workplace cultures in the world. Gallup created the Exceptional Workplace Award to identify excellence and celebrate organizations that incorporate employee engagement into the bedrock of how they do their work, motivate their teams, and achieve business outcomes. "Exact Sciences' success starts with our people, and winning the Gallup Exceptional Workplace Award for the second consecuti

    $EXAS
    Medical Specialities
    Health Care
  • Exact Sciences to Participate in March Investor Conferences

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. TD Cowen Health Care Conference, Boston Fireside chat on Monday, March 3, 2025 at 10:30 a.m. ET Raymond James Institutional Investors Conference, Orlando Presentation on Tuesday, March 4, 2025 at 1:05 p.m. ET The webcasts can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health

    $EXAS
    Medical Specialities
    Health Care

$EXAS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$EXAS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$EXAS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$EXAS
SEC Filings

See more

$EXAS
Leadership Updates

Live Leadership Updates

See more
  • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

    SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

    $EXAS
    $QTRX
    $SERA
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

    CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

    $EXAS
    $GE
    $GMED
    $XRAY
    Medical Specialities
    Health Care
    Consumer Electronics/Appliances
    Technology
  • Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors

    Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also incl

    $EXAS
    $PODD
    Medical Specialities
    Health Care
    Medical/Dental Instruments

$EXAS
Financials

Live finance-specific insights

See more
  • Exact Sciences Announces Fourth Quarter 2024 Results

    Fourth quarter and 2024 highlights Total fourth quarter revenue of $713 million, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $553 million and Precision Oncology revenue of $161 million Total 2024 revenue of $2.76 billion, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $2.10 billion and Precision Oncology revenue of $655 million Plans to launch three new cancer tests in 2025: Cologuard Plus™, next-generation colorectal cancer screening test, Oncodetect™, molecular residual disease test, and Cancerguard™, multi-cancer screening test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic

    $EXAS
    Medical Specialities
    Health Care
  • Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Fourth quarter 2024 webcast & conference call details Date:    Wednesday, February 19, 2025 Time:    5 p.m. ET Webcast:    The live webcast can be accessed at www.exactsciences.com Telephone:    Domestic callers

    $EXAS
    Medical Specialities
    Health Care
  • Exact Sciences Announces Third-Quarter 2024 Results

    Delivered record revenue and cash flow, improved adjusted EBITDA, advanced pipeline Third quarter highlights Total third quarter revenue of $709 million, an increase of 13% on a reported and core revenue basis, including Screening revenue of $545 million and Precision Oncology revenue of $164 million Net loss was $38 million, adjusted EBITDA was $99 million, and adjusted EBITDA margin increased 500 basis points to 14% Operating cash flow was $139 million with free cash flow of $113 million Received FDA approval for the Cologuard Plus™ test, the Company's next-generation Cologuard® test Presented data showing potential of its blood-based colorectal cancer screening test, with sens

    $EXAS
    Medical Specialities
    Health Care

$EXAS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more